search
Back to results

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Candesartan 8mg
Amlodipine 5mg
CKD-330 8/5mg
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Healthy male volunteer, Candesartan, Amlodipine

Eligibility Criteria

19 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male volunteer in the age of 19-45
  2. Body weight ≥ 55 kg and in the range of calculated IBW ±20%
  3. Subject without a hereditary problems, chronic disease and morbid symptom
  4. Suitable clinical laboratory test values
  5. Subject who sign on an informed consent form willingly

Exclusion Criteria:

  1. Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
  2. Gastrointestinal disease or gastrointestinal surgery
  3. History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
  4. Galactose intolerance
  5. Sitting systolic blood pressure ≥ 140 mmHg or< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 beats per minute
  6. Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range
  7. Serum Creatinine > upper limit of normal range
  8. Drug abuse
  9. Subject treated metabolizing enzyme inducers or inhibitors within 1 month
  10. Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
  11. Subject treated Investigational product(include Bioequivalence test) within 3 months
  12. Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
  13. Continuously taking Alcohol > 21 units/week
  14. Cigarette > 10 cigarettes/day
  15. Subjects with planning of dental treatment or any surgery
  16. Another clinical condition in judgement of investigator

Sites / Locations

  • Chungnam National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Candesartan and Amlodipine

CKD-330

Arm Description

Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day

CKD-330 8/5mg, PO, 1day or 22day

Outcomes

Primary Outcome Measures

Cmax(Maximum Plasma Concentration) of Candesartan
AUCt(Area Under the Plasma Concentration-time curve) of Candesartan
Cmax(Maximum Plasma Concentration) of Amlodipine
AUCt(Area Under the Plasma Concentration-time curve) of Amlodipine

Secondary Outcome Measures

AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Candesartan
tmax(Time to reach the maximum concentration) of Candesartan
t1/2β(Time for C max to drop in half) of Candesartan
CL/F(Clearance/Bioavailability) of Candesartan
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Amlodipine
tmax(Time to reach the maximum concentration) of Amlodipine
t1/2β(Time for C max to drop in half) of Amlodipine
CL/F(Clearance/Bioavailability) of Amlodipine

Full Information

First Posted
August 20, 2015
Last Updated
December 4, 2015
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT02548286
Brief Title
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
Official Title
A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers(B)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Healthy male volunteer, Candesartan, Amlodipine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
53 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Candesartan and Amlodipine
Arm Type
Active Comparator
Arm Description
Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
Arm Title
CKD-330
Arm Type
Experimental
Arm Description
CKD-330 8/5mg, PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
Candesartan 8mg
Intervention Description
PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
Amlodipine 5mg
Intervention Description
PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
CKD-330 8/5mg
Intervention Description
PO, 1day or 22day
Primary Outcome Measure Information:
Title
Cmax(Maximum Plasma Concentration) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
AUCt(Area Under the Plasma Concentration-time curve) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
Cmax(Maximum Plasma Concentration) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
AUCt(Area Under the Plasma Concentration-time curve) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Secondary Outcome Measure Information:
Title
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
tmax(Time to reach the maximum concentration) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
t1/2β(Time for C max to drop in half) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
CL/F(Clearance/Bioavailability) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
tmax(Time to reach the maximum concentration) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
t1/2β(Time for C max to drop in half) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
CL/F(Clearance/Bioavailability) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male volunteer in the age of 19-45 Body weight ≥ 55 kg and in the range of calculated IBW ±20% Subject without a hereditary problems, chronic disease and morbid symptom Suitable clinical laboratory test values Subject who sign on an informed consent form willingly Exclusion Criteria: Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system Gastrointestinal disease or gastrointestinal surgery History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs Galactose intolerance Sitting systolic blood pressure ≥ 140 mmHg or< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 beats per minute Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range Serum Creatinine > upper limit of normal range Drug abuse Subject treated metabolizing enzyme inducers or inhibitors within 1 month Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week Subject treated Investigational product(include Bioequivalence test) within 3 months Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month Continuously taking Alcohol > 21 units/week Cigarette > 10 cigarettes/day Subjects with planning of dental treatment or any surgery Another clinical condition in judgement of investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jang Hee Hong, MD, PhD
Organizational Affiliation
Chungnam National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chungnam National University Hospital
City
Daejeon
State/Province
Jung-gu
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

We'll reach out to this number within 24 hrs